Low-dose Gout Drug, Colchicine, Has Been Approved to Reduce Cardiovascular Events in Patients with Coronary Disease
News October 21, 2021 | CanadaOnlineHealth
Pendopharm, a division of Pharmascience Inc., has announced an existing anti-inflammatory gout drug as a new repurposed treatment.
In August 2021, Health Canada issued a Notice of Compliance (NOC) approving Myinfla ER (colchicine 0.5 mg extended-release tablets), a prescription medication for use in the reduction of cardiovascular risks in patients with coronary artery disease.
The approval was primarily based on the results of the Colchicine Cardiovascular Outcomes Trial (COLCOT) led by Dr. Jean-Claude Tardif from the Montreal Heart Institute, in partnership with Pharmascience.
Published in the prestigious New England Journal of Medicine, the results demonstrated that the treatment with low-dose colchicine (0.5 mg) reduces the risk of a first ischemic cardiovascular event by 23% and the risk of overall ischemic events by 34% in patients having suffered a myocardial infarction (Tardif et al., N Engl J Med 2019; 381:2497-505).
Myinfla ER 0.5 mg (colchicine extended-release tablets) is now available in CanadaOnlineHealth.com. For any inquiries, please contact Customer Service at: 1-800-399-DRUG (3784) (Monday - Friday, 8:00 AM to 8:00 PM CST | Saturday - Sunday, 8:00 AM to 4:00 PM CST).
References:
- canada.ca
- yahoo.com
- newswire.ca
- nejm.org
- globenewswire.com